{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:48:43Z","timestamp":1791679723048,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","award":["IMPACT 20743"],"award-info":[{"award-number":["IMPACT 20743"]}],"id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"DOI":"10.1007\/s12185-026-04296-x","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:42:16Z","timestamp":1791668536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular events in aging Japanese people with hemophilia: a 3-year interim analysis of the ADVANCE Japan cohort"],"prefix":"10.1007","author":[{"given":"Yushi","family":"Chikasawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kanematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Takedani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hiroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhisa","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Higasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kagehiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1126-1498","authenticated-orcid":false,"given":"Azusa","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"issue":"3","key":"4296_CR1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jth.15182","volume":"19","author":"S Hassan","year":"2021","unstructured":"Hassan S, Monahan RC, Mauser-Bunschoten EP, van Vulpen LFD, Eikenboom J, Beckers EAM, et al. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018. J Thromb Haemost. 2021;19(3):645\u201353. https:\/\/doi.org\/10.1111\/jth.15182.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"4296_CR2","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/hae.14423","volume":"27","author":"AU Alam","year":"2021","unstructured":"Alam AU, Karkhaneh M, Attia T, Wu C, Sun HL. All-cause mortality and causes of death in persons with haemophilia: a systematic review and meta-analysis. Haemophilia. 2021;27(6):897\u2013910. https:\/\/doi.org\/10.1111\/hae.14423.","journal-title":"Haemophilia"},{"issue":"4","key":"4296_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/bjh.18085","volume":"197","author":"S Shapiro","year":"2022","unstructured":"Shapiro S, Benson G, Evans G, Harrison C, Mangles S, Makris M. Cardiovascular disease in hereditary haemophilia: the challenges of longevity. Br J Haematol. 2022;197(4):397\u2013406. https:\/\/doi.org\/10.1111\/bjh.18085.","journal-title":"Br J Haematol"},{"key":"4296_CR4","doi-asserted-by":"publisher","unstructured":"Fransen van de Putte DE, Fischer K, Makris M, Tait RC, Chowdary P, Collins PW et al. History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia. Eur J Haematol, 2012;89(4):336-9. https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01835.x.","DOI":"10.1111\/j.1600-0609.2012.01835.x"},{"issue":"6","key":"4296_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000918","volume":"7","author":"C Hermans","year":"2023","unstructured":"Hermans C. Thrombosis and hemophilia: little more evidence, much more guidance. Hemasphere. 2023;7(6):e918. https:\/\/doi.org\/10.1097\/hs9.0000000000000918.","journal-title":"Hemasphere"},{"issue":"1","key":"4296_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2022.100007","volume":"7","author":"AD Shapiro","year":"2023","unstructured":"Shapiro AD, Hardesty BM, Peyvandi F, Iorio A. Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: a scoping review. Res Pract Thromb Haemost. 2023;7(1):100007. https:\/\/doi.org\/10.1016\/j.rpth.2022.100007.","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"4296_CR7","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1182\/bloodadvances.2018018226","volume":"2","author":"SL Sood","year":"2018","unstructured":"Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, et al. A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Adv. 2018;2(11):1325\u201333. https:\/\/doi.org\/10.1182\/bloodadvances.2018018226.","journal-title":"Blood Adv"},{"issue":"4","key":"4296_CR8","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1111\/hae.13749","volume":"25","author":"A Nagao","year":"2019","unstructured":"Nagao A, Suzuki N, Takedani H, Yamasaki N, Chikasawa Y, Sawada A, et al. Ischaemic events are rare, and the prevalence of hypertension is not high in Japanese adults with haemophilia: First multicentre study in Asia. Haemophilia. 2019;25(4):e223\u201330. https:\/\/doi.org\/10.1111\/hae.13749.","journal-title":"Haemophilia"},{"issue":"6","key":"4296_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.35772\/ghm.2020.01080","volume":"2","author":"R Nagai","year":"2020","unstructured":"Nagai R, Kubota S, Ogata M, Yamamoto M, Tanuma J, Gatanaga H, et al. Unexpected high prevalence of severe coronary artery stenosis in Japanese hemophiliacs living with HIV-1. Glob Health Med. 2020;2(6):367\u201373. https:\/\/doi.org\/10.35772\/ghm.2020.01080.","journal-title":"Glob Health Med"},{"issue":"7","key":"4296_CR10","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1161\/strokeaha.113.000990","volume":"44","author":"M Hori","year":"2013","unstructured":"Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013;44(7):1891\u20136. https:\/\/doi.org\/10.1161\/strokeaha.113.000990.","journal-title":"Stroke"},{"issue":"1","key":"4296_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/hae.14674","volume":"29","author":"R Klamroth","year":"2023","unstructured":"Klamroth R, Ay C, De Moerloose P, Fontana P, Windyga J, Astermark J, et al. Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - a modified Delphi consensus by the ADVANCE Working Group. Haemophilia. 2023;29(1):21\u201332. https:\/\/doi.org\/10.1111\/hae.14674.","journal-title":"Haemophilia"},{"issue":"4","key":"4296_CR12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/hae.15039","volume":"30","author":"A Nagao","year":"2024","unstructured":"Nagao A, Chikasawa Y, Hiroi Y, Ieko M. Treatment of thrombotic cardiovascular diseases in people with haemophilia: a Japanese consensus study. Haemophilia. 2024;30(4):933\u201342. https:\/\/doi.org\/10.1111\/hae.15039.","journal-title":"Haemophilia"},{"issue":"6","key":"4296_CR13","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1111\/hae.14876","volume":"29","author":"A Nagao","year":"2023","unstructured":"Nagao A, Chikasawa Y, Sawada A, Kanematsu T, Yamasaki N, Takedani H, et al. Haemophilia and cardiovascular disease in Japan: low incidence rates from ADVANCE Japan baseline data. Haemophilia. 2023;29(6):1519\u201328. https:\/\/doi.org\/10.1111\/hae.14876.","journal-title":"Haemophilia"},{"key":"4296_CR14","doi-asserted-by":"publisher","unstructured":"Correction to \"Haemophilia and Cardiovascular Disease in Japan: Low Incidence Rates From ADVANCE Japan Baseline Data\". Haemophilia. 2025;31(6):1358\u201361. https:\/\/doi.org\/10.1111\/hae.70146.","DOI":"10.1111\/hae.70146"},{"issue":"4","key":"4296_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"4296_CR16","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1111\/hae.12596","volume":"21","author":"I Rizwan","year":"2015","unstructured":"Rizwan I, Minuk L, Jackson S, Iorio A. Cardiovascular disease prevalence and relevance in haemophilia: a scoping review. Haemophilia. 2015;21(3):e156\u201366. https:\/\/doi.org\/10.1111\/hae.12596.","journal-title":"Haemophilia"},{"issue":"3","key":"4296_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5482\/hamo-16-09-0037","volume":"37","author":"REG Schutgens","year":"2017","unstructured":"Schutgens REG, Voskuil M, Mauser-Bunschoten EP. Management of cardiovascular disease in aging persons with haemophilia. Hamostaseologie. 2017;37(3):196\u2013201. https:\/\/doi.org\/10.5482\/hamo-16-09-0037.","journal-title":"Hamostaseologie"},{"key":"4296_CR18","doi-asserted-by":"publisher","unstructured":"Fransen van de Putte DE, Fischer K, Makris M, Tait RC, Chowdary P, Collins PW et al. Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thromb Haemost. 2013;109(1):16\u201323. https:\/\/doi.org\/10.1160\/th12-05-0332.","DOI":"10.1160\/th12-05-0332"},{"issue":"Suppl 6","key":"4296_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046.","journal-title":"Haemophilia"},{"issue":"12","key":"4296_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/hr.2009.161","volume":"32","author":"H Arima","year":"2009","unstructured":"Arima H, Yonemoto K, Doi Y, Ninomiya T, Hata J, Tanizaki Y, et al. Development and validation of a cardiovascular risk prediction model for Japanese: the Hisayama study. Hypertens Res. 2009;32(12):1119\u201322. https:\/\/doi.org\/10.1038\/hr.2009.161.","journal-title":"Hypertens Res"},{"issue":"3","key":"4296_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jjcc.2023.08.006","volume":"83","author":"T Ohira","year":"2024","unstructured":"Ohira T, Eguchi E, Hayashi F, Kinuta M, Imano H. Epidemiology of cardiovascular disease in Japan: an overview study. J Cardiol. 2024;83(3):191\u2013200. https:\/\/doi.org\/10.1016\/j.jjcc.2023.08.006.","journal-title":"J Cardiol"},{"issue":"1","key":"4296_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mcna.2011.11.003","volume":"96","author":"R Dhingra","year":"2012","unstructured":"Dhingra R, Vasan RS. Age as a risk factor. Med Clin North Am. 2012;96(1):87\u201391. https:\/\/doi.org\/10.1016\/j.mcna.2011.11.003.","journal-title":"Med Clin North Am"},{"issue":"2","key":"4296_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.atherosclerosissup.2004.03.006","volume":"5","author":"J Tuomilehto","year":"2004","unstructured":"Tuomilehto J. Impact of age on cardiovascular risk: implications for cardiovascular disease management. Atheroscler Suppl. 2004;5(2):9\u201317. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2004.03.006.","journal-title":"Atheroscler Suppl"},{"key":"4296_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12122937","author":"MC Badescu","year":"2022","unstructured":"Badescu MC, Badulescu OV, Butnariu LI, Bararu Bojan I, Vladeanu MC, Dima N, et al. Cardiovascular risk factors in patients with congenital hemophilia: a focus on hypertension. Diagnostics (Basel). 2022. https:\/\/doi.org\/10.3390\/diagnostics12122937.","journal-title":"Diagnostics (Basel)"},{"issue":"Suppl 3","key":"4296_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1365-2516.2010.02262.x","volume":"16","author":"PM Mannucci","year":"2010","unstructured":"Mannucci PM, Mauser-Bunschoten EP. Cardiovascular disease in haemophilia patients: a contemporary issue. Haemophilia. 2010;16(Suppl 3):58\u201366. https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02262.x.","journal-title":"Haemophilia"},{"issue":"9438","key":"4296_CR26","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/s0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(04)17018-9.","journal-title":"Lancet"},{"issue":"2","key":"4296_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372. https:\/\/doi.org\/10.1378\/chest.09-1584.","journal-title":"Chest"},{"issue":"40","key":"4296_CR28","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1093\/eurheartj\/ehab648","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(40):4194. https:\/\/doi.org\/10.1093\/eurheartj\/ehab648.","journal-title":"Eur Heart J"},{"issue":"5","key":"4296_CR29","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.3324\/haematol.2022.282099","volume":"109","author":"PE Alcedo Andrade","year":"2024","unstructured":"Alcedo Andrade PE, Mannucci PM, Kessler CM. Emicizumab: the hemophilia A game-changer. Haematologica. 2024;109(5):1334\u201347. https:\/\/doi.org\/10.3324\/haematol.2022.282099.","journal-title":"Haematologica"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04296-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04296-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04296-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:03:11Z","timestamp":1791676991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04296-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":29,"alternative-id":["4296"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04296-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"27 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was granted investigator-initiated grant funding (IMPACT 20743) from Bayer Yakuhin, Ltd. Y. Chikasawa has received honoraria from Chugai Pharmaceutical, Sanofi Genzyme, Bayer Yakuhin, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, KM Biologics, Japan Blood Products Organization, Fujimoto Pharmaceuticals and CSL-Behring. T. Kanematsu has received honoraria from Chugai Pharmaceutical, Sanofi, KM Biologics, Bayer Yakuhin Ltd and CSL Behring. A. Sawada received honoraria from Sanofi K.K., Takeda Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Fujimoto Pharmaceutical Corporation, Japan Blood Products Organization, Novo Nordisk Pharma Ltd., and CSL Behring. N. Yamasaki has received honoraria from Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Fujimoto Pharmaceutical Corporation, KM Biologics, Pfizer Japan Inc., Novo Nordisk Pharma Ltd., Japan Blood products Organization and CSL Behring. H. Takedani has received honoraria from Chugai Pharmaceutical and Novo Nordisk Pharma. M. Nojima has received consultancy fees from Chugai Pharmaceutical Co. Ltd and Alfresa Pharma Corporation. Y. Hiroi has received honoraria from Otsuka Pharmaceutical Co. Ltd., Novartis, Mochida Pharmaceutical Co. Ltd., Tsumura & Co., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., MSD, Viatris, Edwards Lifesciences, Boehringer Ingelheim, Eisai Co. Ltd., Chugai Pharmaceutical Co. Ltd., AstraZeneca, Ono Pharmaceutical Co. Ltd., Takeda Pharmaceuticals, Daiichi Sankyo and Kowa Company, Ltd. T. Fujii serves as an Editor of the International Journal of Hematology and has received honoraria for lectures from Sanofi, Chugai Pharmaceutical, Takeda Pharmaceutical, Novo Nordisk Pharma, JB, KMB, Pfizer, and CSL Behring, and manuscript or consultant fees from Sanofi, Chugai Pharmaceutical, Takeda Pharmaceutical, Novo Nordisk Pharma, Pfizer, CSL Behring, and Bayer. N. Suzuki has received honoraria from Sanofi, Novo Nordisk Pharma, Chugai Pharmaceutical, Pfizer, Bayer, CSL Behring, Fujimoto pharma, KM biologics, Kissei pharmaceutical, Japan blood products organization and Takeda Pharmaceutical. T. Matsushita has received honoraria from Novo Nordisk Pharma, Chugai Pharmaceutical, Takeda Pharmaceutical, Sanofi, and Bayer, research funding from Novo Nordisk Pharma, Chugai Pharmaceutical, and Pfizer, and scholarship donations from Chugai Pharmaceutical. S. Higasa has received honoraria from Chugai Pharmaceutical, Sanofi, Takeda Pharmaceutical, Novo Nordisk Pharma, CSL Behring and Bayer. K. Amano has received consultancy fees from Chugai Pharmaceutical Co., Ltd; research funding from KM Biologics Co., Ltd; speaker's bureau from Chugai Pharmaceutical Co., Ltd, Sanofi S.A., Bayer AG, Takeda Pharmaceuticals Co. Ltd, Novo Nordisk A\/S, CSL Behring, KM Biologics Co., Ltd, Pfizer Inc., Japan Blood Products Organization, Fujimoto Pharmaceutical Co., Ltd and is listed as an entity\u2019s board of directors or advisory committee member for Chugai Pharmaceutical Co., Ltd and CSL Behring. A. Nagao has received investigator-initiated research\/education grant funding from Bayer Yakuhin Ltd., Pfizer Japan Inc., and Chugai Pharmaceutical Co., Ltd, and serves as a medical advisor for Chugai Pharmaceutical Co., Ltd., KM Biologics, and Novo Nordisk Pharma Ltd, and has received honoraria from Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Fujimoto Pharmaceutical Corporation, KM Biologics, Pfizer Japan Inc., Novo Nordisk Pharma Ltd., Sysmex Corporation, Ono yakuhin, Japan Blood products Organization and CSL Behring.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the ethical standards for research involving human participants and adhered to the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants before study enrollment. The study protocol received approval from the institutional review board (IRB) of each participating institution. Participant data were managed confidentially and stored securely in accordance with relevant data protection requirements. All authors confirm the integrity and accuracy of the data and the adherence of the study to the approved protocol. Potential conflicts of interest were disclosed by all authors in accordance with journal policy. This study was registered in the Japan Registry of Clinical Trials (jRCT1030190046).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}